{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:38:05Z","timestamp":1761946685630},"reference-count":23,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro susceptibilities of 103\n            <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n            isolates, 14\n            <jats:italic>Mycoplasma hominis<\/jats:italic>\n            isolates, 12\n            <jats:italic>Mycoplasma fermentans<\/jats:italic>\n            isolates, and 24\n            <jats:italic>Ureaplasma<\/jats:italic>\n            species to ABT-773, an investigational ketolide, and seven other agents were determined. For\n            <jats:italic>M. pneumoniae,<\/jats:italic>\n            the ABT-773 MIC at which 90% of isolates are inhibited (MIC\n            <jats:sub>90<\/jats:sub>\n            ; \u22640.001 \u03bcg\/ml) was comparable to those of azithromycin, clarithromycin, and erythromycin and at least 128-fold lower than those of levofloxacin, gatifloxacin, moxifloxacin, and doxycycline. For\n            <jats:italic>M. fermentans<\/jats:italic>\n            , the ABT-773 MIC\n            <jats:sub>90<\/jats:sub>\n            (\u22640.008 \u03bcg\/ml) was 2- to 128-fold lower than those of all other agents tested. For\n            <jats:italic>M. hominis<\/jats:italic>\n            , the ABT-773 MIC\n            <jats:sub>90<\/jats:sub>\n            (0.031 \u03bcg\/ml) was equivalent to that of moxifloxacin, 2-fold lower than those of gatifloxacin and clindamycin, and 16-fold lower than that of levofloxacin. ABT-773 was equally active against doxycycline-susceptible and doxycycline-resistant organisms. The ABT-773 MICs (0.016 \u03bcg\/ml) for\n            <jats:italic>Ureaplasma<\/jats:italic>\n            species were the lowest of those of any drug tested. The MIC\n            <jats:sub>90<\/jats:sub>\n            was 4- to 64-fold lower than those of clarithromycin, azithromycin, and erythromycin and \u226516-fold lower than those of all three fluoroquinolones. Minimal bactericidal concentrations determined for a subgroup of organisms were \u22640.063 \u03bcg\/ml for\n            <jats:italic>M. pneumoniae<\/jats:italic>\n            and 0.25 \u03bcg\/ml for\n            <jats:italic>M. fermentans<\/jats:italic>\n            , but they were several dilutions higher for\n            <jats:italic>M. hominis<\/jats:italic>\n            and\n            <jats:italic>Ureaplasma<\/jats:italic>\n            spp. ABT-773 has great potential for further study for the treatment of infections due to mycoplasmas and ureaplasmas.\n          <\/jats:p>","DOI":"10.1128\/aac.47.1.39-42.2003","type":"journal-article","created":{"date-parts":[[2002,12,24]],"date-time":"2002-12-24T04:39:08Z","timestamp":1040704748000},"page":"39-42","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas"],"prefix":"10.1128","volume":"47","author":[{"given":"Ken B.","family":"Waites","sequence":"first","affiliation":[{"name":"Departments of Pathology"},{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"Crabb","sequence":"additional","affiliation":[{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn B.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/39.5.669","volume":"39","year":"1997","unstructured":"B\u00e9b\u00e9ar, C. M., H. Renaudin, M. D. Aydin, J. F. Chantot, and C. B\u00e9b\u00e9ar. 1997. In vitro activity of ketolides against mycoplasmas. J. Antimicrob. Chemother.39:669-670.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1980-1982.2000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199506000-00002"},{"key":"e_1_3_2_5_2","first-page":"29","volume":"45","year":"2000","unstructured":"Duffy, L. B., D. Crabb, and M. C. Kempf. 2000. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline, and clindamycin against Mycoplasma spp. J. Antimicrob. Chemother.45(Suppl. S1):29-33.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.4.547"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00570-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199810000-00004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.790"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0924-8579(01)00462-9","volume":"18","year":"2001","unstructured":"Johnson, C. N., W. H. Benjamin, B. M. Gray, M. J. Crain, K. M. Edwards, and K. B. Waites. 2001. In vitro activities of ABT 773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae isolates from the respiratory tracts of children in the southeastern United States. Int. J. Antimicrob. Agents18:531-535.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2604-2608.2001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2770"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(70)80485-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2163-2168.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2001.tb01293.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/35101544"},{"key":"e_1_3_2_17_2","first-page":"169","volume":"16","year":"1980","unstructured":"Stopler, T., and D. Branski. 1980. Antibiotic-resistant mutants of Mycoplasma pneumoniae. Isr. J. Med. Sci.16:169-173.","journal-title":"Isr. J. Med. Sci."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jac\/18.3.359","volume":"18","year":"1986","unstructured":"Stopler, T., C. B. Gerichter, and D. Branski. 1986. Resistance of Mycoplasma pneumoniae to macrolides, lincomycin, and streptogramin B. J. Antimicrob. Chemother.18:359-364.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1112-1113.2000"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.10.1500"},{"key":"e_1_3_2_21_2","unstructured":"Waites K. B. C. M. B\u00e9b\u00e9ar J. A. Robertson D. F. Talkington and G. E. Kenny. 2001. Cumitech 34 Laboratory diagnosis of mycoplasmal infections. Coordinating ed. F. S. Nolte. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_22_2","unstructured":"Waites K. B. and D. Taylor-Robinson. 1999. Mycoplasma and Ureaplasma p. 782-794. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_23_2","unstructured":"Waites K. B. 2001. Mycoplasma p. 649-655. In D. Schlossberg (ed.) Current therapy of infectious disease 2nd ed. Mosby-Year Book Inc. St. Louis Mo."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1381-1382.2000"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.39-42.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.39-42.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:58:29Z","timestamp":1645466309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.1.39-42.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1128\/AAC.47.1.39-42.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.1.39-42.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2002-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}